References Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia KTE-X19 CAR T-Cell therapy in relapsed or refractory mantle-cell lymphoma Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma Idecabtagene vicleucel in relapsed and refractory multiple myeloma CAR T cells for acute myeloid leukemia: state of the art and future directions Genetic inactivation of CD33 in hematopoietic stem cells to enable CAR T cell immunotherapy for acute myeloid leukemia Treatment of CD33-directed chimeric antigen receptor-modified T cells in one patient with relapsed and refractory acute myeloid leukemia Gene-edited healthy donor CAR T cells show superior anti-tumour activity compared to CAR T cells derived from patients with lymphoma in an in vivo model of high-grade lymphoma ‘Off-the-shelf’ allogeneic CAR T cells: development and challenges Allogene and Celularity move CAR-T therapy off the shelf Graft-versus-host disease risk after chimeric antigen receptor T-cell therapy: the diametric opposition of T cells Acute graft-versus-host disease after humanized anti-CD19-CAR T therapy in relapsed B-ALL patients after allogeneic hematopoietic stem cell transplant Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing Multiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition A versatile system for rapid multiplex genome-edited CAR T cell generation Preclinical evaluation of allogeneic CAR T cells targeting BCMA for the treatment of multiple myeloma Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells Universal allogeneic CAR T cells engineered with Sleeping Beauty transposons and CRISPR-CAS9 for cancer immunotherapy Sleeping Beauty–engineered CAR T cells achieve antileukemic activity without severe toxicities Enhanced CAR T-cell engineering using non-viral Sleeping Beauty transposition from minicircle vectors Genomic analyses of SLAMF7 CAR-T cells manufactured by sleeping beauty transposon gene transfer for immunotherapy of multiple myeloma Genome-wide profiling reveals remarkable parallels between insertion site selection properties of the MLV retrovirus and the piggyBac transposon in primary human CD4+ T cells Anti-CD33 monoclonal antibody m195 for the therapy of myeloid leukemia Gemtuzumab ozogamicin in acute myeloid leukemia CAR density influences antitumoral efficacy of BCMA CAR T cells and correlates with clinical outcome Massively parallel single-cell RNA-seq for marker-free decomposition of tissues into cell types Innate immune landscape in early lung adenocarcinoma by paired single-cell analyses Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas Clonal kinetics and single-cell transcriptional profiling of CAR-T cells in patients undergoing CD19 CAR-T immunotherapy A distinct transcriptional program in human CAR T cells bearing the 4-1BB signaling domain revealed by scRNA-seq Next maSigPro: Updating maSigPro bioconductor package for RNA-seq time series CRISPR/Cas9-mediated glycolate oxidase disruption is an efficacious and safe treatment for primary hyperoxaluria type I INSPIIRED: quantification and visualization tools for analyzing integration site distributions INSPIIRED: A pipeline for quantitative analysis of sites of new DNA integration in cellular genomes IGUIDE: An improved pipeline for analyzing CRISPR cleavage specificity Jin-Soo Kim A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells Assessment of costimulation and coinhibition in a triple parameter T cell reporter line: Simultaneous measurement of NF-κB, NFAT and AP-1 A Jurkat 76 based triple parameter reporter system to evaluate TCR functions and adoptive T cell strategies Two acute monocytic leukemia (AML-M5a) cell lines (MOLM-13 and MOLM-14) with interclonal phenotypic heterogeneity showing MLL-AF9 fusion resulting from an occult chromosome insertion, ins(11;9)(q23;p22p23) Peripheral blood T cells in acute myeloid leukemia (AML) patients at diagnosis have abnormal phenotype and genotype and form defective immune synapses with AML blasts Easy quantitative assessment of genome editing by sequence trace decomposition GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases Engineering and design of chimeric antigen receptors T cell engaging bispecific antibodies targeting CD33 IgV and IgC domains for the treatment of acute myeloid leukemia Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results Highly efficient multiplex human T cell engineering without double-strand breaks using Cas9 base editors Automated generation of gene-edited CAR T cells at clinical scale Efficient non-viral T-cell engineering by sleeping beauty minicircles diminishing DNA toxicity and miRNAs silencing the endogenous T-cell receptors CRISPR-engineered T cells in patients with refractory cancer Targeting cardiac fibrosis with engineered T cells Quantitative evaluation of chromosomal rearrangements in gene-edited human stem cells by CAST-Seq